A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab.
Aged
Anemia, Aplastic
/ chemically induced
Antibodies, Monoclonal, Humanized
/ adverse effects
Antineoplastic Agents, Immunological
/ adverse effects
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Danazol
/ administration & dosage
Estrogen Antagonists
/ administration & dosage
Fatal Outcome
Female
Humans
Lung Neoplasms
/ drug therapy
Lymphatic Metastasis
/ pathology
Aplastic anemia
Danazol
Immune-related adverse events
Non–small cell lung cancer
Pembrolizumab
Journal
Current problems in cancer
ISSN: 1535-6345
Titre abrégé: Curr Probl Cancer
Pays: United States
ID NLM: 7702986
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
21
09
2020
revised:
05
11
2020
accepted:
17
11
2020
pubmed:
10
12
2020
medline:
14
1
2022
entrez:
9
12
2020
Statut:
ppublish
Résumé
Programmed cell death protein 1 immune checkpoint inhibitor is an effective treatment for non-small cell lung cancer. Although hematological immune-related adverse events induced by antiprogrammed-cell-death-protein-1 immunotherapy have been reported, they are rare, and there remain many unknowns. We report the case of a 77-year-old woman with non-small cell lung cancer and pembrolizumab-induced danazol-dependent aplastic anemia. Sixteen days after she received pembrolizumab with carboplatin and pemetrexed as first-line treatments, she developed pancytopenia, including severe thrombocytopenia (1 × 10
Identifiants
pubmed: 33293197
pii: S0147-0272(20)30200-2
doi: 10.1016/j.currproblcancer.2020.100686
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Estrogen Antagonists
0
pembrolizumab
DPT0O3T46P
Danazol
N29QWW3BUO
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100686Informations de copyright
Copyright © 2020. Published by Elsevier Inc.